Cargando…
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
OBJECTIVE: There is a need for comparative studies to provide evidence-based treatment guidance for biologic agents in rheumatoid arthritis (RA). Therefore, this study was undertaken as the first head-to-head comparison of subcutaneous (SC) abatacept and SC adalimumab, both administered along with b...
Autores principales: | Weinblatt, Michael E, Schiff, Michael, Valente, Robert, van der Heijde, Désirée, Citera, Gustavo, Zhao, Cathy, Maldonado, Michael, Fleischmann, Roy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Subscription Services, Inc., A Wiley Company
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572583/ https://www.ncbi.nlm.nih.gov/pubmed/23169319 http://dx.doi.org/10.1002/art.37711 |
Ejemplares similares
-
Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016) -
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014) -
Brief Report: Estimating Disease Activity Using Multi‐Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab
por: Fleischmann, Roy, et al.
Publicado: (2016) -
Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011) -
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration
por: Schiff, Michael, et al.
Publicado: (2016)